

Leukemia

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged \geq 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT02670044 2015-003386-28
GH29914

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible for cytotoxic therapy.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT02670044 2015-003386-28 GH29914
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
 \geq 18 Years

Healthy Volunteers
No
